Stock STTK SHATTUCK LABS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
7.49 USD 0.00% Intraday chart for Shattuck Labs, Inc. -5.37% +5.05%
May. 14 Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress CI
May. 02 Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

Number of employees: 75

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
1 100.0 % 2 100.0 % +154.14%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 2 100.0 % +154.14%

Managers

Managers TitleAgeSince
Taylor Schreiber FOU
 Founder 44 15-12-31
Andrew Neill DFI
 Director of Finance/CFO 38 19-06-30
Stephen Stout CMP
 Compliance Officer 49 20-12-31
Lini Pandite CTO
 Chief Tech/Sci/R&D Officer 65 17-06-30
Amy Franke CTO
 Chief Tech/Sci/R&D Officer - 22-09-30
Abhinav Shukla CTO
 Chief Tech/Sci/R&D Officer 51 21-05-31
Conor Richardson IRC
 Investor Relations Contact - 18-12-31
Suresh de Silva PRN
 Corporate Officer/Principal 45 18-11-30
George Fromm
45 -
Thomas M. Lampkin LAW
 General Counsel - 18-03-31

Members of the board

Members of the board TitleAgeSince
Neil Gibson BRD
 Director/Board Member 67 16-10-31
George Golumbeski CHM
 Chairman 67 17-12-31
Michael Lee BRD
 Director/Board Member 45 20-05-31
Helen Boudreau BRD
 Director/Board Member 58 20-07-21
Taylor Schreiber FOU
 Founder 44 15-12-31
Carrie Brownstein BRD
 Director/Board Member 54 21-10-21
Tyler Brous BRD
 Director/Board Member 41 16-08-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,550,872 41,211,268 ( 86.67 %) 0 86.67 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.98 %
7,121,147 14.98 % 70 M $
Redmile Group LLC
11.81 %
5,615,489 11.81 % 55 M $
Redmile Group LLC
11.81 %
5,615,489 11.81 % 55 M $
Prosight Management LP
7.834 %
3,725,000 7.834 % 36 M $
Josiah Hornblower
6.262 %
2,977,627 6.262 % 29 M $
Taylor Schreiber
5.526 %
2,627,802 5.526 % 26 M $
Adage Capital Partners GP LLC
4.984 %
2,370,000 4.984 % 23 M $
Vanguard Global Advisers LLC
3.827 %
1,819,926 3.827 % 18 M $
Franklin Advisers, Inc.
3.496 %
1,662,516 3.496 % 16 M $
The Clark Estates, Inc.
3.103 %
1,475,648 3.103 % 14 M $

Company contact information

Shattuck Labs, Inc.

500 West 5th Street Suite 1200

78701, Austin

+

http://www.shattucklabs.com
address Shattuck Labs, Inc.(STTK)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Shattuck Labs, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.49 USD
Average target price
15.5 USD
Spread / Average Target
+106.94%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SHATTUCK LABS, INC. Stock Shattuck Labs, Inc.
+5.05% 356M
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. STTK Stock
  4. Company Shattuck Labs, Inc.